

(12) INTERNATIONAL PUBLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number  
WO 2004/033428 A1

(51) International Patent Classification<sup>7</sup>: C07D 211/58,  
413/14, 409/14, 401/14, 471/04, 405/14, 417/14

Beerse (BE). DIELS, Gaston, Stanislas, Marcella  
[BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30,  
B-2340 Beerse (BE).

(21) International Application Number:

PCT/EP2003/050697

(74) Common Representative: JANSSEN PHARMACEU-  
TICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(22) International Filing Date: 7 October 2003 (07.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PCT/EP02/11328 8 October 2002 (08.10.2002) EP

PCT/EP02/14836

23 December 2002 (23.12.2002) EP

(71) Applicant (for all designated States except US):  
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-  
houtseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JANSSENS, Frans,  
Eduard [BE/BE]; Janssen Pharmaceutica N.V., Turnhout-  
seweg 30, B-2340 Beerse (BE). SOMMEN, François,  
Maria [BE/BE]; Janssen Pharmaceutica N.V., Turnhout-  
seweg 30, B-2340 Beerse (BE). DE BOECK, Benoît,  
Christian, Albert, Ghislain [BE/BE]; Janssen Pharma-  
ceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).  
LEENAERTS, Joseph, Elisabeth [BE/BE]; Janssen Pharma-  
ceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).  
VAN ROOSBROECK, Yves, Emiel, Maria [BE/BE];  
Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

[Continued on next page]

(54) Title: SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ AN-  
TAGONISTS



(57) Abstract: The invention concerns substituted 1,4-di-piperidin-4-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK<sub>1</sub> antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of emesis, anxiety, depression, pain, pancreatitis and IBS. The compounds according to the invention can be represented by general Formula (I), and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1. In view of their capability to antagonize the actions of neurokinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P by blocking the NK<sub>1</sub> receptor, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of neurokinin-mediated conditions, such as, for instance CNS disorders, in particular depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, schizoaffective disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions; inflammation; allergic disorders; emesis; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders; vasospastic diseases; fibrosing and collagen diseases; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control.



— of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

International Application No

PCT 03/50697

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/58 C07D413/14 C07D409/14 C07D401/14 C07D471/04  
C07D405/14 C07D417/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/16440 A (JANSSEN PHARMACEUTICA NV ; JANSSENS FRANS EDUARD (BE); SOMMEN FRANCOIS) 9 May 1997 (1997-05-09) cited in the application claims -----	1,6,8

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

28 January 2004

Date of mailing of the international search report

10/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Diederens, J

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT 03/50697

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9716440	A	09-05-1997	
		AT 188691 T	15-01-2000
		AU 704155 B2	15-04-1999
		AU 7493296 A	22-05-1997
		BR 9611184 A	30-03-1999
		CA 2234096 A1	09-05-1997
		CN 1438220 A	27-08-2003
		CN 1205699 A , B	20-01-1999
		CY 2177 A	23-08-2002
		CZ 9801322 A3	16-09-1998
		DE 69606196 D1	17-02-2000
		DE 69606196 T2	21-09-2000
		EA 980404 A1	29-10-1998
		WO 9716440 A1	09-05-1997
		EP 0862566 A1	09-09-1998
		ES 2143238 T3	01-05-2000
		GR 3033154 T3	31-08-2000
		HR 960507 A1	28-02-1998
		HU 9802985 A2	28-10-1999
		IL 123962 A	11-01-2001
		JP 11514634 T	14-12-1999
		JP 3073238 B2	07-08-2000
		NO 981534 A	24-06-1998
		NZ 321575 A	28-05-1999
		PL 327406 A1	07-12-1998
		PT 862566 T	30-06-2000
		SI 862566 T1	30-04-2000
		TR 9800756 T2	21-07-1998
		TW 460473 B	21-10-2001
		US 6197772 B1	06-03-2001
		US 6521621 B1	18-02-2003
		US RE37886 E1	15-10-2002
		ZA 9609090 A	29-04-1998